Duality Biologics
Clinical-stage biotechnology company developing antibody-drug conjugates for solid tumors.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 2 · Recruiting · Solid Tumors
First-in-human Study of DB-1419 for Advanced/Metastatic Solid TumorsPhase 1 · Recruiting · Solid Tumor, Adult
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE ParticipantsPhase 1 · Recruiting · Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPhase 1 · Recruiting · HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsPhase 1 · Recruiting · Advanced Solid Tumors
A Study of DB-1310 in Advanced/Metastatic Solid TumorsPhase 1 · Recruiting · Advanced Solid Tumor
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/duality-biologics/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.